Citi raised the firm’s price target on Glaukos (GKOS) to $135 from $125 and keeps a Buy rating on the shares. The firm adjusted targets in the medical technology group as part of a Q1 preview. The “walls of worry are high” into the earnings reports with the sector undergoing significant multiple compression, the analyst tells investors in a research note. Citi removed iRhythm and Medtronic as top picks. The firm’s top picks are now Edwards Lifesciences and Intuitive Surgical.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GKOS:
- Seaport Research med technology analyst holds analyst/industry conference call
- Glaukos announces commercial availability of Epioxa HD/Epioxa
- Glaukos management to meet with Piper Sandler
- Glaukos Highlights Interventional Ophthalmology Strategy in Investor Update
- Glaukos Expands Eye Care Pipeline With New GLK-321 Trial in Demodex Blepharitis